Around 200,000 more children have had health insurance since the start of the COVID-19 pandemic; when FDA-approved bivalent COVID-19 vaccines for younger children are expected to be available in early to mid-October; one study compared metformin plus sitagliptin, liraglutide, glimepiride, and insulin glargine for maintaining blood sugar levels.
More children have had health insurance since the start of the COVID-19 pandemic
According to Stateline, more children have acquired health insurance since the start of the COVID-19 pandemic. According to an analysis of US Census Bureau data by Georgetown University’s Center for Children and Families, the child non-insurance rate was 5.4% in 2021 and 5.7% in 2019. This percentage change reflects approximately 200,000 more children with health insurance in 2021 compared to 2019. That “small but significant drop,” the center says, likely stems from a provision passed by Congress that prohibited states from barring individuals from Medicaid during the pandemic. In 2021, around 4.2 million children were still uninsured.
Bivalent vaccines for younger children expected by mid-October
If approved by the FDA, bivalent COVID-19 vaccines for younger children are expected to be available by mid-October, the CDC said in a vaccine planning guide. Pfizer’s booster would be available for children between the ages of 5 and 11, and Moderna’s for children between the ages of 6 and 17. Currently, Pfizer and Moderna’s updated boosters — designed to be more effective against the Omicron variant — are approved for ages 12 and up and 19 and up, respectively. If these bivalent boosters are approved for younger children, mRNA COVID-19 vaccines may no longer be approved as booster doses.
Insulin glargine, liraglutide performed better than 2 other diabetes drugs
A large clinical study found that insulin glargine and liraglutide were better at keeping blood sugar levels in the recommended range in people with type 2 diabetes than two other FDA-approved drugs. In the National Institutes of Health study, 3 groups of patients received metformin plus sitagliptin, liraglutide, or glimepiride, all of which increase insulin levels. The fourth group of patients received metformin plus insulin glargine U-100, a long-acting insulin. Those who received metformin plus liraglutide or insulin glargine achieved and maintained blood glucose goals about 6 months longer than those who received sitagliptin, which was the least effective at maintaining goal levels. However, the study authors noted that neither combination performed overwhelmingly better, as nearly three-quarters of the participants failed to maintain target levels through 4 years of follow-up.